Abstract:Objective To observe the efficacy and safety of Carrelizumab combined with Arotinib in the treatment of small cell lung cancer (SCLC). Methods A total of 76 patients with SCLC who were admitted to Jiujiang First People′s Hospital from November 2017 to October 2019 were selected as research objects. They were divided into control group and observation group according to random number table method, with 38 cases in each group. The control group was treated with Arotinib, and the observation group was treated with Carrelizumab combined with Arotinib, with a course of treatment every 3 weeks and 6 consecutive courses of treatment. The clinical efficacy, quality of life, progression-free survival (PFS), overall survival (OS) and adverse reactions were compared between the two groups. Results There was no statistical significance in objective response rate (ORR) and disease control rate (DCR) between the two groups (P>0.05). After 2, 4 and 6 courses of treatment, the Karnofsky score (KPS) of the observation group was higher than that of the control group, and the OS and PFS of the observation group were longer than those of the control group, the differences were statistically significant (P<0.05). There was no statistical significance between the two groups in the total incidence of adverse reactions (P>0.05). Conclusion Patients with SCLC treated with Carrelizumab combined with Arotinib have better effect, which is conducive to improving the quality of life, prolonging the survival time of patients and reducing toxic and side effects.
李言冰;石鑫;蔡玲玉;左宏波;王志. 卡瑞利珠单抗联合安罗替尼治疗小细胞肺癌的效果及安全性[J]. 中国当代医药, 2022, 29(2): 82-84转88.
LI Yanbing ;SHI Xin ;CAI Lingyu ;ZUO Hongbo ;WANG Zhi. Efficacy and safety of Carrelizumab combined with Arotinib in the treatment of small cell lung cancer. 中国当代医药, 2022, 29(2): 82-84转88.